These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 28084045)

  • 1. Tapentadol for Cancer Pain Management: A Narrative Review.
    Carmona-Bayonas A; Jiménez Fonseca P; Virizuela Echaburu J
    Pain Pract; 2017 Nov; 17(8):1075-1088. PubMed ID: 28084045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR for the Management of Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-Label, Phase 3b/4 Study.
    Baron R; Likar R; Martin-Mola E; Blanco FJ; Kennes L; Müller M; Falke D; Steigerwald I
    Pain Pract; 2016 Jun; 16(5):580-99. PubMed ID: 26095455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of tapentadol as a strong opioid in cancer pain management: a systematic and critical review.
    Mercadante S
    Curr Med Res Opin; 2017 Nov; 33(11):1965-1969. PubMed ID: 28906155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tapentadol Prolonged Release for Chronic Pain: A Review of Clinical Trials and 5 Years of Routine Clinical Practice Data.
    Baron R; Eberhart L; Kern KU; Regner S; Rolke R; Simanski C; Tölle T
    Pain Pract; 2017 Jun; 17(5):678-700. PubMed ID: 27611642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic review of tapentadol in chronic severe pain.
    Riemsma R; Forbes C; Harker J; Worthy G; Misso K; Schäfer M; Kleijnen J; Stürzebecher S
    Curr Med Res Opin; 2011 Oct; 27(10):1907-30. PubMed ID: 21905968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of tapentadol in severe chronic pain in Spain: a cost analysis of data from RCTs.
    Obradovic M; Ikenberg R; Hertel N; Antoñanzas F; Gálvez R; Liedgens H
    Clin Ther; 2012 Apr; 34(4):926-43. PubMed ID: 22417717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour-related pain.
    Kress HG; Koch ED; Kosturski H; Steup A; Karcher K; Dogan C; Etropolski M; Eerdekens M
    Eur J Pain; 2016 Oct; 20(9):1513-8. PubMed ID: 27062079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Tapentadol prolonged release improves analgesia, functional impairment and quality of life in patients with chronic pain who have previously received oxycodone/naloxone].
    Kern KU; Krings D; Waldmann-Rex S
    MMW Fortschr Med; 2014 Jul; 156 Suppl 2():54-63. PubMed ID: 25351028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of tapentadol prolonged release compared with oxycodone controlled release in the UK in patients with severe non-malignant chronic pain who failed 1st line treatment with morphine.
    Ikenberg R; Hertel N; Moore RA; Obradovic M; Baxter G; Conway P; Liedgens H
    J Med Econ; 2012; 15(4):724-36. PubMed ID: 22364286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study.
    Gálvez R; Schäfer M; Hans G; Falke D; Steigerwald I
    Adv Ther; 2013 Mar; 30(3):229-59. PubMed ID: 23475406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective, multicenter, open-label study of the clinical efficacy of tapentadol extended-release in the treatment of cancer-related pain and improvement in the quality of life of opioid-naïve or opioid-resistant patients.
    Jung JY; Chon HJ; Choi YJ; Yeon SE; Choi SY; Lee KH
    Support Care Cancer; 2022 Jul; 30(7):6103-6112. PubMed ID: 35420330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tapentadol PR for Pain Syndromes in Real Life Patients with Hematological Malignancy.
    Brunetti GA; Palumbo G; Morano GS; Baldacci E; Carmosino I; Annechini G; Talone R; Kiflom S; Mastrogiacomo G; Grammatico S; Chisini M; Costa A; Tendas A; Scaramucci L; Giovannini M; Niscola P; Petrucci MT; Cartoni C
    Cardiovasc Hematol Agents Med Chem; 2016; 14(1):68-74. PubMed ID: 27048320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of tapentadol ER for managing moderate to severe chronic pain.
    Afilalo M; Morlion B
    Pain Physician; 2013 Jan; 16(1):27-40. PubMed ID: 23340531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tapentadol is effective in the management of moderate-to-severe cancer-related pain in opioid-naïve and opioid-tolerant patients: a retrospective study.
    Sazuka S; Koitabashi T
    J Anesth; 2020 Dec; 34(6):834-840. PubMed ID: 32648017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical simulation model of long-acting opioids for treatment of chronic non-cancer pain in the United States.
    Neil N; Merchant S; Provenzano D; Ogden K; Mody SH
    J Med Econ; 2013; 16(2):307-17. PubMed ID: 23216013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of tapentadol for first-line opioid-resistant neuropathic pain in Japan.
    Sugiyama Y; Kataoka T; Tasaki Y; Kondo Y; Sato N; Naiki T; Sakamoto N; Akechi T; Kimura K
    Jpn J Clin Oncol; 2018 Apr; 48(4):362-366. PubMed ID: 29506199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of prolonged-release oxycodone/naloxone on outcomes affecting patients' daily functioning in comparison with extended-release tapentadol: a systematic review.
    Thakur D; Dickerson S; Kumar Bhutani M; Junor R
    Clin Ther; 2015 Jan; 37(1):212-24. PubMed ID: 25592091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tapentadol for the management of cancer pain in adults: an update.
    Boland JW
    Curr Opin Support Palliat Care; 2023 Jun; 17(2):90-97. PubMed ID: 36919687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tapentadol extended release for chronic pain patients.
    Taylor R; Pergolizzi JV; Raffa RB
    Adv Ther; 2013 Jan; 30(1):14-27. PubMed ID: 23328938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Tapentadol prolonged release for the treatment of severe chronic tumor pain in routine clinical practice].
    Agbalaka A; Schwenke K; Litzenburger B
    MMW Fortschr Med; 2012 Dec; 154 Suppl 4():123-30. PubMed ID: 23326931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.